Accepted at 6:40 p.m. Feb, 21, 2025 by mitchelnelson
Author: gio_fronti02
Co-authors: mitchelnelson
Related Note: 1488768082952 1
Rationale for change

Warfarin too can be used for ppx in patients at risk of stroke events with underlying afib (FA2024 pag441, Hemonc pharm), so the card should at least give a clue in the second close as in why Direct factor Xa inhibitors are the right answer.

nid:1488765259902

Source: Other - FA2024

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy

Watch Heparin, LMWH, Fondaparinux, Direct Thrombin Inhibitors, Xa Inhibitors
Sketchy 2

Watch Narrow-Complex Tachycardia: AFib & AFlutter Management


Watch Ischemic Stroke Treatment

Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize



Watch Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban)
Physeo
Also used for DVT and PE
Bootcamp
Watch associated Bootcamp video - Coagulation and Fibrinolysis: Anticoagulation
OME

Additional Resources
One by one
Empty field
#AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::05_Retired_Lessons::02_Narrow_Complex_Tachycardia_2_AFib_AFlutter_SOA_MAT_SOAP_[OLD_VERSION] #AK_Step2_v12::#UWorld::Step::4452 #AK_Step2_v12::#UWorld::Step::6881 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::04_Direct_coagulation_factor_inhibitors::*Direct_Factor_Xa_Inhibitors #AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::04_Tachycardia::04_Narrow_Complex_Tachycardia:_AFib_&_AFlutter_Management #AK_Step2_v12::#SketchyNeurology::06_Neurovascular::04_Stroke_Management::02_Ischemic_Stroke_Treatment #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #PANCE::EOR::Family_med #AK_Step1_v12::#UWorld::Step::15390 #AK_Step2_v12::#B&B::02_Cardio::01_Arrhythmias::03_Atrial_Fibrillation_and_Flutter #AK_Step1_v12::#B&B::15_Neuro::03_Neurovascular_Disorders::05_Management_of_TIA/Stroke::Extra #AK_Step1_v12::#UWorld::COMLEX::26286 #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::02_DirectThrombinInhibitors_DirectFactorXaInhibitors #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#AMBOSS::7C04tR #AK_Step2_v12::#AMBOSS::ht0cW3 #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::01_Heparin,_LMWH,_fondaparinux,_direct_thrombin_inhibitors,_Xa_inhibitors #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #PANCE::CARDIO::conduction_disorders/dysrhythmias #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step1_v12::#B&B::11_Hematology::01_Hemostasis::07_Anticoagulant_Drugs::Extra #PANCE::EOR::IM #AK_Step2_v12::#UWorld::#UWSA1 #AK_Step2_v12::!Shelf::IM !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::09_Factor_Xa_Inhibitors_(Apixaban/Rivaroxaban/Edoxaban) #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants::Extra #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step2_v12::#AMBOSS::TB06Zi #PANCE::EOR::EM #AK_Step2_v12::#UWorld::COMLEX::101238